 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral,IM,IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50 to 75% (oral) 78% (intramuscular) |
| Protein binding | 40% |
| Metabolism | Hepatic |
| Eliminationhalf-life | 4 to 5 hours |
| Excretion | Renal, 10 to 14% unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.021.675 |
| Chemical and physical data | |
| Formula | C14H22BrN3O2 |
| Molar mass | 344.253 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Bromopride (INN) is adopamine antagonist withprokinetic properties widely used as anantiemetic, closely related tometoclopramide. It is not available in theUnited States.
Bromopride appears to be safe and effective for use in pregnancy.[1]
Bromopride is indicated in the treatment ofnausea andvomiting, includingpostoperative nausea and vomiting (PONV);gastroesophageal reflux disease (GERD/GORD); and as preparation forendoscopy andradiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications,hiccups and gastrointestinal adverse effects ofradiation therapy.
Bromopride is generally well tolerated; the most commonadverse effects of its use aresomnolence and fatigue. Bromopride may rarely causeextrapyramidal symptoms and, as with metoclopramide, may increaseprolactin levels.[2]
Bromopride is asubstitutedbenzamide, closely related tometoclopramide.[3] It is identical to metoclopramide except for the presence of abromine atom where metoclopramide has achlorine substituent.
Bromopride is not available in the United States or the United Kingdom. It is marketed inBrazil bySanofi-Synthélabo under the trade nameDigesan, by LIBBS under the name Plamet, and as ageneric drug.